These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 23896722)
1. Selective serotonin 3 receptor antagonist treatment for schizophrenia: meta-analysis and systematic review. Kishi T; Mukai T; Matsuda Y; Iwata N Neuromolecular Med; 2014 Mar; 16(1):61-9. PubMed ID: 23896722 [TBL] [Abstract][Full Text] [Related]
2. A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia. Noroozian M; Ghasemi S; Hosseini SM; Modabbernia A; Khodaie-Ardakani MR; Mirshafiee O; Farokhnia M; Tajdini M; Rezaei F; Salehi B; Ashrafi M; Yekehtaz H; Tabrizi M; Akhondzadeh S Psychopharmacology (Berl); 2013 Aug; 228(4):595-602. PubMed ID: 23515583 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of perospirone in schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Kishi T; Iwata N CNS Drugs; 2013 Sep; 27(9):731-41. PubMed ID: 23812802 [TBL] [Abstract][Full Text] [Related]
4. Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study. Khodaie-Ardakani MR; Seddighi S; Modabbernia A; Rezaei F; Salehi B; Ashrafi M; Shams-Alizadeh N; Mohammad-Karimi M; Esfandiari GR; Hajiaghaee R; Akhondzadeh S J Psychiatr Res; 2013 Apr; 47(4):472-8. PubMed ID: 23375406 [TBL] [Abstract][Full Text] [Related]
5. Adjunctive ondansetron for schizophrenia: A systematic review and meta-analysis of randomized controlled trials. Zheng W; Cai DB; Zhang QE; He J; Zhong LY; Sim K; Ungvari GS; Ning YP; Xiang YT J Psychiatr Res; 2019 Jun; 113():27-33. PubMed ID: 30878789 [TBL] [Abstract][Full Text] [Related]
6. The efficacy of 5-HT3 receptor antagonists for the prevention of postoperative nausea and vomiting after craniotomy: a meta-analysis. Neufeld SM; Newburn-Cook CV J Neurosurg Anesthesiol; 2007 Jan; 19(1):10-7. PubMed ID: 17198095 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Oya K; Kishi T; Iwata N Hum Psychopharmacol; 2014 Sep; 29(5):483-91. PubMed ID: 25087702 [TBL] [Abstract][Full Text] [Related]
9. NMDA receptor antagonists interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled trials. Kishi T; Iwata N J Psychiatr Res; 2013 Sep; 47(9):1143-9. PubMed ID: 23692933 [TBL] [Abstract][Full Text] [Related]
10. Serotonin 3 receptor antagonists for obsessive-compulsive disorder: A systematic review and pairwise meta-analysis. Hamanaka S; Kishi T; Sakuma K; Nishii Y; Hatano M; Iwata N J Psychiatr Res; 2023 Nov; 167():132-138. PubMed ID: 37866327 [TBL] [Abstract][Full Text] [Related]
11. A network meta-analysis on the efficacy of serotonin type 3 receptor antagonists used in adults during the first 24 hours for postoperative nausea and vomiting prophylaxis. Tang DH; Malone DC Clin Ther; 2012 Feb; 34(2):282-94. PubMed ID: 22296947 [TBL] [Abstract][Full Text] [Related]
12. Blonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trials. Kishi T; Matsuda Y; Nakamura H; Iwata N J Psychiatr Res; 2013 Feb; 47(2):149-54. PubMed ID: 23131856 [TBL] [Abstract][Full Text] [Related]
13. Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis. Kishi T; Matsuda Y; Iwata N Psychopharmacology (Berl); 2017 Jul; 234(14):2113-2125. PubMed ID: 28508107 [TBL] [Abstract][Full Text] [Related]
14. Comparative safety and effectiveness of serotonin receptor antagonists in patients undergoing chemotherapy: a systematic review and network meta-analysis. Tricco AC; Blondal E; Veroniki AA; Soobiah C; Vafaei A; Ivory J; Strifler L; Cardoso R; Reynen E; Nincic V; Ashoor H; Ho J; Ng C; Johnson C; Lillie E; Antony J; Roberts DJ; Hemmelgarn BR; Straus SE BMC Med; 2016 Dec; 14(1):216. PubMed ID: 28007031 [TBL] [Abstract][Full Text] [Related]
15. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study. Modabbernia A; Rezaei F; Salehi B; Jafarinia M; Ashrafi M; Tabrizi M; Hosseini SM; Tajdini M; Ghaleiha A; Akhondzadeh S CNS Drugs; 2013 Jan; 27(1):57-65. PubMed ID: 23233269 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials. Citrome L; Meng X; Hochfeld M; Stahl SM Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738 [TBL] [Abstract][Full Text] [Related]
17. Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study. Zhang ZJ; Kang WH; Li Q; Wang XY; Yao SM; Ma AQ Schizophr Res; 2006 Dec; 88(1-3):102-10. PubMed ID: 16959472 [TBL] [Abstract][Full Text] [Related]
18. Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial. Akhondzadeh S; Mohammadi N; Noroozian M; Karamghadiri N; Ghoreishi A; Jamshidi AH; Forghani S Schizophr Res; 2009 Feb; 107(2-3):206-12. PubMed ID: 18789844 [TBL] [Abstract][Full Text] [Related]
19. Antiemetic prophylaxis in thyroid surgery: a randomized, double-blind comparison of three 5-HT3 agents. Metaxari M; Papaioannou A; Petrou A; Chatzimichali A; Pharmakalidou E; Askitopoulou H J Anesth; 2011 Jun; 25(3):356-62. PubMed ID: 21431625 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of noradrenalin reuptake inhibitor augmentation therapy for schizophrenia: a meta-analysis of double-blind randomized placebo-controlled trials. Kishi T; Mukai T; Matsuda Y; Moriwaki M; Iwata N J Psychiatr Res; 2013 Nov; 47(11):1557-63. PubMed ID: 23899496 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]